Advertisement


Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

David A. Hyman, MD, JD, on Inclusive Shared Savings

Welcome and Introduction to Vi3C

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Advertisement